MIR: Expect Opportunities As New Partnerships And Index Inclusions Shape Outlook

Analysts have raised their price target for Mirion Technologies from $26.29 to $31.29 per share. They cite improving revenue growth forecasts, despite a modest increase in the discount rate and a slightly lower expected profit margin.

Analysts have raised their price target for Mirion Technologies from $25.67 to $26.29. They cite updated models that reflect modest improvements in fair value estimates, even though there have been some adjustments to profit margin assumptions.

Analysts have raised their price target for Mirion Technologies from $23.50 to $25.67. They cite expectations of significantly improved revenue growth and profit margins, as well as a more favorable future price-to-earnings outlook.

The consensus analyst price target for Mirion Technologies has increased modestly, while both the discount rate and future P/E ratio remain virtually unchanged, resulting in a slightly higher fair value estimate of $23.50. What's in the News Mirion Technologies entered into a strategic partnership with Westinghouse Electric to provide digital Ex-core Nuclear Instrumentation Systems, modernizing legacy neutron flux monitoring for global PWR operators.

Mirion Technologies' consensus price target has been revised upward, primarily reflecting a notable improvement in net profit margin and a substantial decline in future P/E, which together indicate stronger profitability and a more attractive valuation. What's in the News Mirion Technologies updated 2025 earnings guidance with higher expected revenue growth of 7.0%-9.0% (previously 5.0%-7.0%), factoring in FX and acquisition tailwinds; organic revenue growth revised to 5.0%-7.0% (previously 5.5%-7.5%).

The notable increase in Mirion Technologies’ future P/E and simultaneous decline in net profit margin suggest higher valuation expectations despite weaker profitability, leading analysts to raise the price target from $20.60 to $22.20. What's in the News Mirion Technologies raised full-year 2025 revenue growth guidance to 7.0%-9.0% (from 5.0%-7.0% prior), factoring in a foreign exchange and acquisition tailwind, but trimmed organic growth expectations due to weakness in Labs & Research and Dosimetry markets.

AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.1%.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.